Drug Eases Blood Sugar and Weight in Type 1 Diabetes

In a small early trial, adults with type 1 diabetes and extra weight saw better glucose control and weight loss on the drug.

Updated on Nov. 6, 2026 in Diabetes

Bold flat-color editorial illustration of a single unlabeled pen injector lying diagonally on a matte surface, with a droplet at the needle tip, evoking a new treatment approach for type 1 diabetes.
A small early trial found that adding the drug acmopatide to insulin improved blood sugar control and promoted weight loss in 111 adults with type 1 diabetes and overweight or obesity. AI Illustration. Upload story photo >

A Phase 2 trial tested acmopatide, added to standard insulin therapy, in 111 adults with type 1 diabetes and overweight or obesity. Participants on the drug showed better blood sugar control and weight loss than those on placebo, which may matter most to people with type 1 diabetes who also carry extra weight.

Why it matters

People with type 1 diabetes often struggle to reach glucose targets, face acute metabolic risks, and are increasingly living with overweight or obesity, a combination that existing insulin-based care does not fully address. Early-stage evidence like this helps researchers judge whether a non-insulin add-on could address both blood sugar and weight at once.

This randomized, placebo-controlled Phase 2 trial enrolled 111 patients with type 1 diabetes and a BMI of at least 27 kg/m2 and measured changes over 16 weeks. Results are preliminary: the trial was small and short, and the source does not establish durability or safety beyond the study window.

The players

University of North Carolina at Chapel Hill

A public research university whose institution is the affiliation of the trial's lead author; it has a broad research program in metabolic and diabetes science.

The details

Acmopatide was given on top of standard insulin therapy, with participants randomly assigned to one of three doses (1.8 mg, 4.1 mg, or 6.6 mg) or placebo. The primary measure was the percent change in HbA1C, a marker of average blood sugar over several months, at week 16. No deaths, severe hypoglycemia events, or diabetic ketoacidosis events were reported during the study.

Timeline

  1. Primary end points, including HbA1C and weight changes, were measured at week 16 of the trial.

Health Landscape

Current type 1 diabetes care relies primarily on insulin, and few add-on therapies exist for patients with overweight or obesity. This Phase 2 result places acmopatide among early candidates aimed at that gap, though it remains at the pre-Phase 3 stage.

If you live with type 1 diabetes and carry extra weight, this research suggests that weight and blood sugar may one day be addressed together, though no treatment is available from this trial. It is worth discussing with your doctor whether your current insulin plan is meeting your glucose and weight goals.

The takeaway

Adding a non-insulin therapy to type 1 diabetes care is an active area of study, and this early trial shows promising signals for both blood sugar and weight. Ask your physician whether ongoing trials in this area might be relevant to your care.

Further reading

For broader context on how treatment options are evolving, explore our Diabetes coverage.

Source note: This article includes information reported by Derm Immuno Today.